Many patients seek genetic testing to see if they have mutations in their genes that areassociated with a significantly increased risk of breast or ovarian cancer. Respondent MyriadGenetics obtained patents on two human genes thatcorrelate to this risk, known as BRCA1 and BRCA2.These patents claim every naturally-occurringversion of those genes, including mutations, on thetheory that Myriad invented something patent-eligible simply by removi
ng (“isolating”) the genes
from the body. Petitioners are primarily medicalprofessionals who regularly use routine, conventionalgenetic testing methods to examine genes, but areprohibited from examining the human genes thatMyriad claims to own.The question presented is: Are human genespatentable?
LIST OF PARTIES
The petitioners are the Association forMolecular Pathology, American College of MedicalGenetics and Genomics, American Society forClinical Pathology, College of American Pathologists,Haig Kazazian, MD, Arupa Ganguly, PhD, WendyChung, MD, PhD, Harry Ostrer, MD, DavidLedbetter, PhD, Stephen Warren, PhD, EllenMatloff, M.S., Elsa Reich, M.S., Breast Cancer
Action, Boston Women’s Health Book Collective
,Lisbeth Ceriani, Runi Limary, Genae Girard, PatriceFortune, Vicky Thomason, and Kathleen Raker. Therespondents are Myriad Genetics, Inc., and in theirofficial capacity as directors of the University of UtahResearch Foundation, Lorris Betz, Roger Boyer, Jack